High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.

The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA). Between 1990 and 2000, 610 children with localized NB were included in the Localized Neuroblastoma 90 (NBL 90) and NBL 94 study from the French Society of Pediatric Oncology. Among them, 32 children had MNA with Stage II or III NB. During the first period of the study, 20 children (Group A) received postoperative conventional chemotherapy (CT) and/or radiotherapy (RT), depending on each patient's postoperative status. Subsequently, because of a high recurrence rate, the next 12 children (Group B) were given postoperative high-dose CT (HDC) (busulfan and melphalan) with stem cell rescue (SCR) followed by RT in addition to conventional postoperative CT. The two groups were comparable with regard to prognostic factors (age, location of the primary lesion, International Neuroblastoma Staging System stage, lymph node invasion) and response to preoperative CT. The 6-year overall survival rate was significantly different between the two groups 25% +/- 10% in Group A vs. 83% +/- 11% in Group B; P = 0.004). Postoperative intensification treatment with HDC, SCR, and locoregional RT resulted in higher survival rates when compared with standard treatment alone and should be considered in the treatment plan for children who are diagnosed with Stage II or III NB and MYCN amplification.

Laprie A ，Michon J ，Hartmann O ，Munzer C ，Leclair MD ，Coze C ，Valteau-Couanet D ，Plantaz D ，Carrie C ，Habrand JL ，Bergeron C ，Chastagner P ，Défachelles AS ，Delattre O ，Combaret V ，Bénard J ，Pérel Y ，Gandemer V ，Rubie H ，Neuroblastoma Study Group of the French Society of Pediatric Oncology ... -  《CANCER》

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

George RE ，London WB ，Cohn SL ，Maris JM ，Kretschmar C ，Diller L ，Brodeur GM ，Castleberry RP ，Look AT ... -  《JOURNAL OF CLINICAL ONCOLOGY》

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

Schmidt ML ，Lal A ，Seeger RC ，Maris JM ，Shimada H ，O'Leary M ，Gerbing RB ，Matthay KK ... -  《JOURNAL OF CLINICAL ONCOLOGY》

Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.

Minard V ，Hartmann O ，Peyroulet MC ，Michon J ，Coze C ，Defachelle AS ，Lejars O ，Perel Y ，Bergeron C ，Boutard P ，Leverger G ，Stephan JL ，Thyss A ，Chastagner P ，Couillault G ，Devalck C ，Lutz P ，Mechinaud F ，Millot F ，Plantaz D ，Rialland X ，Rubie H ... -  《-》

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

Canete A ，Gerrard M ，Rubie H ，Castel V ，Di Cataldo A ，Munzer C ，Ladenstein R ，Brichard B ，Bermúdez JD ，Couturier J ，de Bernardi B ，Pearson AJ ，Michon J ... -  《-》